STING1 and neoplasm: The major cellular mechanisms of the STING-mediated anticancer immunity involve type I IFN–induced activation and maturation of dendritic cells (DC), which facilitate cross-presentation of tumor-associated antigens to naïve CD8 T cells in the tumor-draining lymph node and/or in the tumor itself (13, 17, 18).